Review

. 2021 Mar 8;39(3):310-345.

doi: 10.1016/j.ccell.2020.11.009. Epub 2020 Dec 17.

Immunomodulation by targeted anticancer agents

Giulia Petroni¹, Aitziber Buqué¹, Laurence Zitvogel², Guido Kroemer³, Lorenzo Galluzzi⁴

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
² Gustave Roussy Cancer Center, Villejuif, France; INSERM U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France; Faculty of Medicine, Paris-Saclay University, Le Kremlin-Bicêtre, France.
³ Equipe Labellisée Par La Ligue Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China; Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. Electronic address: kroemer@orange.fr.
⁴ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA; Université de Paris, Paris, France. Electronic address: deadoc80@gmail.com.

PMID: 33338426
DOI: 10.1016/j.ccell.2020.11.009

Free article

Review

Immunomodulation by targeted anticancer agents

Giulia Petroni et al. Cancer Cell. 2021.

Free article

. 2021 Mar 8;39(3):310-345.

doi: 10.1016/j.ccell.2020.11.009. Epub 2020 Dec 17.

Authors

Giulia Petroni¹, Aitziber Buqué¹, Laurence Zitvogel², Guido Kroemer³, Lorenzo Galluzzi⁴

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
² Gustave Roussy Cancer Center, Villejuif, France; INSERM U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France; Faculty of Medicine, Paris-Saclay University, Le Kremlin-Bicêtre, France.
³ Equipe Labellisée Par La Ligue Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China; Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. Electronic address: kroemer@orange.fr.
⁴ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA; Université de Paris, Paris, France. Electronic address: deadoc80@gmail.com.

PMID: 33338426
DOI: 10.1016/j.ccell.2020.11.009

Abstract

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.

Keywords: BRAF; CD8(+) cytotoxic T lymphocytes; CDK4/CDK6; CGAS signaling; DNA damage response; EGFR; KRAS; T(REG) cells; TGF-β; immune checkpoint blockers; immunogenic cell death.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests L.Z. reports research funding from Bristol Myers Squibb, Roche, Glaxo Smyth Kline, Lytix Pharma, Incyte, Merus, and Tusk and Pileje (completed); from Innovate Pharma, Kaleido, Transgene, Elior, Carrefour (ongoing); consulting/advisory honoraria from Transgene, EpiVax, and Lytix; and a co-founder role in everImmune. G.K. reports research funding from Bayer HealthCare, Genentech, Glaxo Smyth Kline, Institut Mérieux, Lytix, PharmaMar, and Sotio and Vasculox (completed); funding from Samsara; consulting/advisory honoraria from The Longevity Labs and Lytix; membership of the Executive Board of Bristol Myers Squibb Foundation France; and co-founder roles with everImmune, Samsara therapeutics, and Therafast Bio. L.G. reports research funding from Lytix and Phosplatin (completed), and consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, The Longevity Labs, Inzen, and the Luke Heller TECPR2 Foundation. All other authors have no conflicts of interest to declare.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Molecular Biology Databases
- Mouse Genome Informatics (MGI)
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immunomodulation by targeted anticancer agents

Affiliations

Immunomodulation by targeted anticancer agents

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Research Materials

Miscellaneous